BACKGROUND: Overall survival (OS) is a critical endpoint in adjuvant trials but requires long durations to events and significant patient resources. In the current study, the authors assessed whether disease-free survival (DFS) can be an early clinical surrogate for OS in the adjuvant setting for localized renal cell carcinoma (RCC). METHODS: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the authors performed a systematic literature review of PubMed and the American Society of Clinical Oncology, European Society for Medical Oncology, and ClinicalTrial.gov Web sites . Inclusion in the current study required randomized controlled trials (RCTs) of adjuvant systemic therapy for localized RCC after nephrectomy with 3 years of outcomes data. Data regarding hazard ratios (HRs) and 5-year event-free rates from Kaplan-Meier estimates were extracted. A trial-level meta-analysis correlated estimates of 5-year DFS and 5-year OS as well as treatment effects (HRs) on these endpoints, weighted by the number of DFS events. R-squared 0.7 was prespecified as being indicative of a strong correlation and the potential for surrogacy. RESULTS: Thirteen RCTs encompassing 6473 patients who were treated with a variety of systemic therapies met eligibility. Only a modest correlation was observed between 5-year DFS and 5-year OS rates (R-squared, 0.48; 95% confidence interval, 0.14-0.67) and between treatment effects as measured by DFS and OS HRs (R-squared, 0.44; 95% confidence interval, 0.00-0.69). CONCLUSIONS: Across RCTs of adjuvant systemic therapy for localized RCC, there was no strong correlation noted between 5-year DFS and 5-year OS rates or between treatment effects on these endpoints. These results highlight the need to identify alternative and more rapid clinical or biologic endpoints to hasten drug development and improve clinical outcomes. Cancer 2018;124:925-33.
INTRODUCTION
Although nephrectomy can be highly curative for patients with localized renal cell carcinoma (RCC), > 30% of patients will develop disease recurrence due to the presence of micrometastatic disease at the time of surgery. 1 In the last 10 years, targeted therapies consisting of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin inhibitors have formed the backbone of treatment to control metastatic disease. 2 Although they provide clinical benefits for the great majority of patients, these agents rarely are curative and the majority of patients ultimately die of their disease. Targeting and eliminating micrometastatic disease in conjunction with surgery is a critical unmet need in patients with RCC.
Despite many decades of investigation into various cytokine-based immunotherapies, vaccines, and chemotherapies, to the best of our knowledge no adjuvant systemic therapy has been proven to increase overall survival (OS). Seeking to capitalize on the efficacy of the targeted therapies in patients with advanced disease and with the goal of eliminating micrometastatic disease, the latest generation of adjuvant studies have centered on testing these agents after nephrectomy. The forerunner was the phase 3 ASSURE (Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma) trial (Eastern Cooperative Oncology Group 2805), a National Clinical Trials Network study that compared 1 year of sunitinib or sorafenib with placebo after surgical resection. 3 Although this trial demonstrated no benefit with regard to disease-free survival (DFS) or OS with adjuvant vascular endothelial growth factor receptor blockade, a subsequent industry-sponsored phase 3 study known as S-TRAC (Sunitinib Treatment Of Renal Adjuvant Cancer) revealed a significant increase of >1 year in DFS with the addition of 1 year of adjuvant sunitinib after nephrectomy. 4 A third phase 3 randomized study evaluated 1 year of adjuvant pazopanib but the study did not meet its primary endpoint of improving DFS compared with placebo. 5 Several other maturing adjuvant studies evaluating other targeted therapies and testing durations (eg, 1 vs 3 years of sorafenib) will be informative.
Although OS often is considered a gold-standard metric in adjuvant studies, it requires trials of long duration and the commitment of significant patient and field resources. The majority of patients who develop metastatic disease die of kidney cancer. Thus, decreasing the incidence of metastatic events may be a surrogate for OS. Intermediate clinical endpoints such as DFS and recurrence-free survival (RFS) are established surrogates for OS and US Food and Drug Administration-sanctioned endpoints in the adjuvant setting for colon cancer and melanoma. To the best of our knowledge, there currently is no validated intermediate clinical endpoint for OS in patients with non-metastatic RCC. In the current study, we explored whether DFS could be a possible earlier surrogate endpoint with which to assess the clinical efficacy of adjuvant agents in patients with kidney cancer. We used a meta-analytic validation approach of aggregated trial data, which has been widely used in other types of cancer. [6] [7] [8] [9] 
MATERIALS AND METHODS

Search Strategy and Selection Criteria
We performed a systematic literature review after the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 10 to identify randomized controlled trials for adjuvant systemic therapy in localized RCC, which reported on both DFS and OS. Automated searches of PubMed, Web site abstract databases from the American Society of Clinical Oncology and the European Society for Medical Oncology, and ClinicalTrials.gov were performed in October 2016. We cross-referenced various permutations of the terms "renal cell carcinoma," "adjuvant pharmaceutical," "adjuvant immunologic," and "clinical trial" in PubMed from January 1966 to October 2016 and from 2004 to 2016 in the other databases. Articles and abstracts were screened in accordance with the PRISMA guidelines (Fig. 1) . 3, 10 The criteria for study inclusion included phase 2 or 3 randomized controlled trials written in English and that reported on both OS and DFS or its alternatives such as RFS or event-free survival (EFS). A minimum of 3 years follow-up was required to ensure a reliable estimate of OS and DFS rates at 5 years. Studies without sufficient follow-up to capture these endpoints or no published results were excluded from analysis.
Data Extraction
Each included study was reviewed in full by at least 4 investigators (L.C.H., W.X., R.M., and G.R.A.). The following information was extracted: first author's name, year of publication, trial phase, year of first and last enrollment, number of enrolled patients, number of patients included in the primary analysis, treatment arms, key patient characteristics, median follow-up, and outcomes data regarding OS and the intermediate endpoints ( 
Definitions of Endpoints
DFS was defined from the time of randomization or nephrectomy to the first evidence of clinical disease recurrence (locoregional or distant) or death from any cause. The alternate terms, RFS and EFS, also were frequently used but were defined similarly as DFS (see Supporting Information Table 1 for trial-specific definition). OS was defined from the time of randomization or nephrectomy to death from any cause. Studies that reported cancerspecific survival (CSS) but not OS were only included in an additional sensitivity analysis.
Statistical Analysis
The trial-level analysis incorporated DFS and OS data as defined and reported in the published trials. HRs from Cox regression were used to quantify the treatment effect (ie, experimental vs control arm) for OS and DFS. For trials that did not report a HR but presented the number of events in each arm and a log-rank P value, we calculated the HR using the methods developed by Tierney et al. 11 The 5-year eventfree rates from the Kaplan-Meier estimates by study and treatment arm were summarized for each endpoint.
We assessed the surrogacy of DFS with OS by use of a correlation analysis. 7 Two levels of correlation analysis were conducted at the trial level. First, we performed linear regression analysis between study-specific and treatment arm-specific Kaplan-Meier estimates of the 5-year OS rate versus Kaplan-Meier estimates of the DFS rate at 3 years, 4 years, and 5 years. Second, we fit a linear regression model to reflect treatment effects using the natural log (HR) on OS versus treatment effects on DFS. Regression was weighted by DFS events. R-squared was used to quantify the percentage of variance explained by the regressions. Based on a review of the literature, a meaningful correlation in oncology tends to be considered when R-squared is 0.7. 7, 9, 12 To check the assumptions of linear regression, we inspected the scatter plots of residuals versus predicted values.
Model accuracy was assessed by a leave-1-out crossvalidation. Each trial was left out once and the linear regression model, weighted by DFS events, was rebuilt on the remaining n-1 trials. This model then was applied to the left-out trial to obtain the predicted treatment effect (log [HR]) on OS, along with 95% prediction intervals (accounted for the weight of the left-out trial). R-squared also was calculated from the remaining n-1 trials model to evaluate the impact of a single trial on the correlation between treatment effects on DFS and OS.
Two studies reported CSS instead of OS. A sensitivity analysis was performed including these additional studies with a CSS endpoint. 
RESULTS
Of the > 300 studies screened, only 13 randomized controlled trials met the prespecified criteria for eligibility and were performed between 1985 and 2016 ( Fig. 1) . 3, 4, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The ASSURE trial by Haas et al 3 was analyzed as 2 separate studies given that it contained 2 parallel, independent experimental treatment arms. The placebo group was downweighted (ie, only 50% of DFS events were counted) in all weighted analyses because it was included twice. Therefore, a total of 14 studies were evaluated. The key eligibility criteria of the trials, enrollment period, drug(s) used, median ages of the patients, and definitions of the intermediate endpoints were captured (Table 1) 3,4, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] (see Supporting Information Tables S1 and S2 ). The treatments encompassed a spectrum of standard therapies at the time for metastatic disease as well as investigational agents, including cytokine-based immunotherapies (interferon-a and interleukin-2), chemotherapies (5-fluorouracil and thalidomide), autologous vaccines or tumor-derived peptides, the carbonic anhydrase IX antibody girentuximab, and the more recently available vascular endothelial growth factor receptor tyrosine kinase inhibitors sunitinib and sorafenib (Table 1) . 3, 4, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] None of the studies have reported a benefit in OS for any of the agents when administered adjuvantly.
Combined, these trials enrolled a total of 6473 patients (Table 1) . 3, 4, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The median follow-up across the trials was 5.1 years (range, 3.3-10 years). All studies before 2006 used an observation control whereas the more modern targeted therapy studies were placebo control studies. Across the trials, the duration of adjuvant therapy ranged from 8 weeks to 3 years. Trial sample size ranged from 46 to 1943 participants. Studies dating to before 2000 were found to be significantly smaller, with none comprising >300 patients.
Data regarding 5-year DFS, CSS, and OS endpoints, event numbers, and the HR for treatment effect were collated (Table 2) .
3,4,13-23 All individual trial endpoints were not found to be statistically significant, with the exception of DFS on the S-TRAC study. 4 Using the published Kaplan-Meier curve, we estimated the 5-year OS for this study to be 0.82 for both treatment arms. The reported OS at the time of publication of the S-TRAC study was not statistically significant (HR, 1.01; 95% CI, 0.72-1.44).
In a trial-level meta-analysis of the 11 included studies with both DFS and OS endpoints (encompassing 22 treatment and control arms), we found a modest weighted correlation (R-squared, 0.48; 95% CI, 0.14-0.67 [22 arms ]) between the 5-year DFS and 5-year OS rates (Fig. 2) (Table 3) . Similarly, there was no strong correlation noted across the treatment effects (ie, the natural log [HR]) between the studies (R-squared, 0.44; 95% CI, 0.00-0.69) (Fig. 3) (Table 3 ). The regression assumptions of linearity and homoscedasticity appeared to be met with the plots of the residual versus predicted values randomly scattering around the zero line from left to right (data not shown).
Sensitivity analyses included 2 additional studies that reported CSS 18, 20 instead of OS and provided similar results, with a modest R-squared of 0.48 for the 5-year DFS and OS/CSS correlation and an R-squared of 0.54 for the treatments effects (Table 3) . Additional sensitivity analyses were performed to assess for a correlation with earlier endpoints of 3-year and 4-year DFS rates and 5-year OS rates. The R-squared of these earlier metrics remained consistent, with the results obtained for 5-year DFS ranging from 0.44 to 0.48 for both time points (Table 3) (Fig. 2) .
On performance of a leave-1-out cross-validation model, the observed HRs of OS fell within the 95% Figure 2 . Kaplan-Meier estimates of overall survival (OS) at 5 years versus disease-free survival (DFS) at 3 years, 4 years, and 5 years. The analysis unit is by study and treatment arm. Circle size is proportional to the number of DFS events in each study and treatment arm.
prediction intervals in all trials, indicating the accuracy of the model (see Supporting Information Fig. 1 ). It is interesting to note that some trials had a large prediction interval due to their small sample size. Across the leave-1-out models, the median R-squared was 0.44 (range, 0.37-0.60) (see Supporting Information Fig. 2) . Therefore, even if a certain trial was removed from the model, the overall R-squared of the model remained consistent with our primary results, namely that of no strong correlation between DFS and OS.
DISCUSSION
To the best of our knowledge, as of 2016, there was no adjuvant systemic therapy proven to enhance cure rates beyond surgical resection alone in patients with RCC. A major challenge for adjuvant studies is the long durations required to demonstrate improvements in conventional clinical endpoints such as OS. Although it is a statistically rigorous endpoint, OS may have several undesirable qualities. The long time-to-event rates mandate studies with large sample sizes to demonstrate statistically and clinically meaningful benefits, 24 which then translate into a higher financial burden, increased use of patient and field resources, and delays in approval of life-prolonging therapies on the order of 5 to 10 years. Furthermore, the ongoing advances in the treatments for metastatic RCC, such as the recent approvals of 3 agents within the last 2 years (nivolumab, cabozantinib, and lenvatinib), all of which improve OS, [25] [26] [27] may confound evaluations of OS. Identifying intermediate clinical endpoints for OS are especially necessary in the adjuvant setting, in which trial durations remain the longest. Extrapolating from metastatic RCC, treatment effects on progression-free survival (PFS) appear to correlate with OS, 28, 29 and the US Food and Drug Administration has recognized PFS as a reasonable endpoint with which to earn regulatory approval in patients with metastatic RCC. However, the development of active secondary therapies in the modern era for metastatic disease has been found to weaken PFS/ overall survival surrogacy correlations both in patients with metastatic melanoma 30 and those with RCC. 28 The latter is not surprising given that the current treatment armamentarium for metastatic RCC currently is comprised of 12 systemic agents that enhance PFS, OS, or both. Indeed, the earliest phase 3 studies that earned regulatory approval for the first 3 targeted agents for metastatic RCC (sorafenib, sunitinib, and bevacizumab) [31] [32] [33] [34] did not Abbreviations: 95% CI, 95% confidence interval; CSS, cancer-specific survival; DFS, disease-free survival; HR, hazard ratio; LN, natural log-transformed; OS, overall survival. a A total of 22 arms from 10 trials; the study by Wood et al 23 was excluded because the 5-year rates were not available. b A total of 24 arms from 11 trials; the studies by Wood et al 23 and Margulis et al 18 were excluded because the 5-year rates were not available. c A total of 11 trials; the trial by Hinotsu et al 17 was excluded because DFS HRs could not be calculated due to incomplete information. d A total of 12 trials; the trials by Hinotsu et al 17 and Naito et al 20 were excluded because HRs could not be calculated due to incomplete information. Figure 3 . Correlation between treatment effects using the overall survival (OS) hazard ratio versus the disease-free survival (DFS) hazard ratio. Values were natural log-transformed and fit with weighted linear regression. Circle size is proportional to the number of DFS events in each study. The prediction intervals were constructed using the mean weights of the included trials. 3, 4, [13] [14] [15] [16] 19, [21] [22] [23] 95% CI indicates 95% confidence interval.
demonstrate a definite improvement in OS, which was at least partly attributed to crossover or subsequent access to these effective targeted therapies. In the current study, which to our knowledge is the first meta-analysis of surrogacy in patients with nonmetastatic RCC, we explored the potential use of a frequently used, earlier intermediate clinical endpoint, DFS, as a surrogate for OS among patients with localized RCC who were being treated with adjuvant therapies. Across the 13 eligible studies with reported DFS and OS data encompassing >6400 patients, correlation between 5-year DFS and OS rates was modest at an R-squared of 0.48. It did not meet our a priori minimum threshold of 0.7 to consider DFS a relevant candidate for OS surrogacy. Similarly, when we evaluated the effects of treatment on DFS and OS, no strong correlation was detected (R-squared, 0.44). Although the current literature suggests there are no established, universal criteria that define how strong a correlation is required to claim surrogacy, investigations in prostate cancer and other malignancies generally have not claimed surrogacy when the R-squared was < 0.7. Thus, we chose this threshold to be consistent with other oncologic surrogacy assessments.
The modern trials, ARISER (Adjuvant Rencarex Immunotherapy Phase 3 Trial to Study Efficacy in Nonmetastatic RCC), ASSURE, S-TRAC, and PROTECT (Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma), all have demonstrated that even intermediate endpoints such as median DFS and RFS require 5 years to demonstrate results. The reported median DFS from each of these studies was approximately 6 to 7 years. A more near-term readout such as 2-year or 3-year DFS would be a more clinically useful and more rapid surrogate for OS. In addition, capturing the impact of early events may have a stronger correlation with OS and would not be diluted by late indolent disease recurrences, which may not contribute to the disease-specific mortality rate. In the current study of trial-level data, no strong correlation with 5-year OS rates was observed no matter which DFS time point was evaluated. Future, more nuanced meta-analyses of individual patient-level data from the recent and maturing targeted therapy adjuvant trials may better address this question. In addition to more intensive investigation of the modern targeted therapy studies, the ongoing perioperative immunotherapy studies such as the National Clinical Information Table S1 ). However, in this adjuvant RCC cohort of patients with a median age of 60 years (see Supporting Information Table S2 ) and a median follow-up of approximately 5 years, RCC mortality without disease recurrence would be rare. Furthermore, the impact of comorbidities should be consistent across both treatment arms given their randomization. Therefore, we do not believe that this surrogacy evaluation was impacted by small differences in these metrics.
In the metastatic RCC setting, Delea et al highlighted publication bias toward positive studies as a potential limitation of some meta-analyses. 28 In the current study, we encountered the opposite issue, in which all but one adjuvant study were negative and the range of treatment effects was small (eg, HRs for DFS ranging from 0.76-1.46). However, considering the generally small sample sizes of many of the studies published before 2000, collating the data of the existing randomized controlled studies performed in the modern adjuvant setting of nonmetastatic RCC was a logical step in an effort to identify efficacy correlations.
In the new era of immuno-oncology in RCC, it also is critical to recognize that these short-term clinical endpoints may not be optimal metrics for efficacy. Unlike what has been noted with the molecularly targeted agents in metastatic RCC, PFS does not appear to correlate with OS with the checkpoint inhibitor nivolumab in metastatic RCC.
In a phase 3 randomized study, nivolumab improved the median OS by nearly 6 months compared with everolimus, despite no difference being noted in the median PFS (4.6 months vs 4.4 months). 35 This discrepancy between PFS and OS is not a new phenomenon for immunotherapies tested in patients with genitourinary cancers (eg, sipuleucel-T, Prostvac (rilimogene galvacirepvec/rilimogene glafolivec)), 36, 37 and may be attributed to the time it takes for these immune-stimulating agents to engage the immune system and induce a subsequent slowing of disease velocity. In anticipation of this potential issue, the next-generation checkpoint inhibitor studies in RCC should be designed with the power to detect both PFS and OS endpoints.
Ultimately, the identification of novel, more rapid clinical readouts are critically needed, and attempts at identifying earlier milestones are ongoing across multiple tumor types. 38 Untapped resources include predictive baseline or on-therapy metrics that would be attainable in a significantly shorter period of time. Indeed, we are most poised to accomplish these objectives with the latest generation of perioperative studies in patients with localized RCC, some of which incorporate neoadjuvant therapeutic strategies. The presurgical administration of immune therapies allows for the investigation of both baseline immune and clinical markers as well as the discovery of on-therapy, pharmacodynamic immune biomarkers. These metrics have high potential to serve as truly nearterm surrogates that can predict OS in the adjuvant setting and rapidly (on the order of 2-3 months).
Future meta-analyses of more mature trials in the modern era of adjuvant targeted therapy are needed to evaluate the surrogacy of intermediate endpoints. Currently, adjuvant randomized controlled trials should continue to evaluate both DFS and OS as the primary measures of clinical benefit, in addition to assessing toxicity and quality of life during adjuvant therapy. Further granularity may be achieved by examining individual patient-level clinical and biologic data from the completed and ongoing adjuvant studies to assess innovative and more near-term time points for surrogacy than are commonly reported.
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